Please login to the form below
Torisel
This page shows the latest Torisel news and features for those working in and with pharma, biotech and healthcare.
Opdivo cleared for kidney cancer and first-line melanoma
The FDA notes that Opdivo is the first drug to show an improvement in overall survival in RCC since Novartis' Torisel (temsirolimus), which was approved in 2007.
Latest news
-
Getting the GIST
Several mTOR antagonists have already been launched for different cancers and could therefore be prescribed as off-label therapy; these include everolimus (Zortress/Certican, Novartis), sirolimus (Rapamune, Wyeth) and temsirolimus (Torisel,
-
Extending the arsenal
Phase I trials are also under way in paediatric patients with recurrent solid tumours, either as a monotherapy or in combination with temsirolimus (Torisel; Pfizer), which is an inhibitor of mTOR,
-
NICE approves Pfizer's kidney cancer drug
NICE has approved Pfizer's Sutent as a kidney cancer first line treatment, but turned down Roche's Avastin, Bayer's Nexavar and Wyeth's Torisel. ... The body also turned down Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus), despite
-
NICE recommends Sutent
Sutent was originally reviewed along with Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), and Wyeth's Torisel (temsirolimus) as part of a multiple technology appraisal.
-
Falling Economy
The four drugs for advanced kidney cancer – Sutent, Nexavar, Avastin and Torisel – could be released from their ban and made available on the NHS for treatment of advanced kidney cancer patients.
More from news
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Mirna hires former Pfizer director as CMO
Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
